Scottt Rottinghaus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Driscoll children hospitalUnited statesJamie fergieScottt rottinghausJohn devincenzoTom wilkinsonEnanta pharmaceuticals incEnanta pharmaceuticalsTexasam universityUniversity of southamptonGlobal institute for hispanic healthHost virtual key opinion leader eventDiscuss advancesTreatment landscapeRespiratory syncytial virusMedical director

Enanta Pharma (ENTA) Reports Positive Data From a Phase 1 Clinical Study of EDP-323

Enanta Pharma (ENTA) Reports Positive Data From a Phase 1 Clinical Study of EDP-323
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesScottt rottinghausJennifer vieraEnanta pharmaceuticals incCenters for disease control preventionExchange commissionEnanta pharmaceuticalsDrug administrationCenters for diseaseFast trackSenior vice presidentChief medical officerDisease controlRespiratory syncytial virusYoung children

Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

- Generally Safe and Well-Tolerated up to 800 mg for Seven Days with Pharmacokinetics Supportive of Once-Daily Dosing - All Doses Resulted in Strong Exposure Multiples Against Both RSV A and B. | June 20, 2023

United statesScottt rottinghausEnanta pharmaceuticals incDrug administrationExchange commissionEnanta pharmaceuticalsCenters for diseaseFast trackSenior vice presidentChief medical officerDisease control

Oral Therapy for Respiratory Syncytial Virus Gets Fast Track Designation

The FDA has granted Fast Track designation to EDP-323, an oral L-protein inhibitor, for the treatment of RSV.

Scottt rottinghausEnanta pharmaceuticalsDrug administrationFast trackSenior vice presidentChief medical officer

Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that the U.S. Food and Drug Administration has. | April 6, 2023

United statesScottt rottinghausDrug administrationExchange commissionCenters for diseaseEuropean congressEnanta pharmaceuticalsEnanta pharmaceuticals incFast trackSenior vice presidentChief medical officerClinical microbiologyInfectious diseasesDisease controlNc stock exchangePress release